Recommend Recommend:  0
+ Post New Thread
Results 1 to 2 of 2

Thread: IGF 1 And MK-677 Used In Clinical Trial For Treatment of CNS Disorders

  1. #1
    Ph.D. P.E.D. Kinesiology Intramuscular Injection Certified Board Certified MD Presser's Avatar
    Join Date
    May 2002
    Posts
    37,668
    M-Chem Coin = $1
    124
    Rep Power
    10

    Default IGF 1 And MK-677 Used In Clinical Trial For Treatment of CNS Disorders



    Arimidex, Letrozole, Clomid, Nolvadex, Caborgoline, Dostinex, Post Cycle Therapy



    igf 1 lr3, igf-1, insulin-like growth factor-1,


    SARM Rad 140 , testolone, sarm s23, Ligandrol, Andarine, Ostarine, Cardarine
    IGF 1 lr3 as we know is a fantastic growth factor for bodybuilders and athletes of all kinds. Used for Building quality lean muscle mass, as well as for its ability to keep you lean by way of signa;ling the body to burn fat for energy. We have also read and posted many studies here at MuscleChemistry regarding Insulin-like growth factor 1 healing power and regenerative capabilities on tendons and cartlidge and it promotes collagen synthesis as well. But lately I have been reading a ton on IGF 1 treatment for Central Nervous System Disorders.

    So Enjoy:

    The therapeutic potential of IGF-1 was found to be relevant to the treatment of several CNS disorders, most notably Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Alzheimerís Disease, Parkinsonís Disease, and autism spectrum disorder. Table 1 categorizes the human clinical trials in specific CNS diseases.
    Table 1

    Clinical Trials with IGF-1 in CNS DisordersOverview of clinical trials using IGF-1 as a therapeutic agent in CNS disorders to date

    Intervention Author
    and Year
    Sample
    Size
    Study
    Design
    Duration
    of
    Treatment
    Primary
    Outcome
    Measure
    Outcome
    Multiple
    Sclerosis
    rhIGF-1 (J. A. Frank et al., 2002) 7 Open-label
    crossover
    6 months Contrast
    enhancing lesion
    frequency on
    MRI
    Negative
    Amyotrophic
    Lateral
    Sclerosis
    rhIGF-1 (Nagano, Shiote, et al., 2005) 9 Double-
    blind,
    randomized
    clinical
    9 months Norris Scales Positive
    Amyotrophic
    Lateral
    Sclerosis
    rhIGF-1 (Lai et al., 1997) 141 Double
    blind,
    placebo
    controlled,
    parallel
    group
    9 months Appel
    Amyotrophic
    Lateral Sclerosis
    rating scale
    Positive
    Amyotrophic
    Lateral
    Sclerosis
    rhIGF-1 (Borasio et al., 1998) 183 Double
    blind,
    placebo
    controlled,
    parallel
    group
    9 months Appel
    Amyotrophic
    Lateral Sclerosis
    rating scale
    Negative
    Amyotrophic
    Lateral
    Sclerosis
    rhIGF-1 (Sorenson et al., 2008) 330 Double
    blind,
    placebo
    controlled,
    parallel
    group
    2 years Rate of change
    in the averaged
    manual muscle
    testing score
    (MMT)
    Negative
    Alzheimerís
    Dementia
    MK-677 (Sevigny et al., 2008) 563 Double
    blind,
    placebo
    controlled,
    parallel
    group
    12 months Clinicianís
    Interview Based
    Impression of
    Change with
    caregiver input
    (CIBIC-plus)
    Negative
    Phelan-
    McDermid
    syndrome
    rhIGF-1 (Kolevzon et al., 2014) 9 Double
    blind,
    placebo
    controlled,
    crossover
    3 months Aberrant
    Behavior
    Checklist-Social
    Withdrawal
    subscale
    Positive
    Rett
    syndrome
    rhIGF-1 (Khwaja et al., 2014) 9
    (MAD)
    12
    (OLE)
    Unblind
    multiple
    ascending
    dose and
    open label
    extension
    4 week
    MAD
    20 week
    OLE
    Multiple
    Cardiorespiratory
    measures
    Positive

    Open in a separate window
    Abbreviations: MK-677 = ibutamoren mesylate; MAD = multiple ascending dose; OLE = open-label extension






    The extensive investigation of the effect of IGF-1 during development and the continued discovery of its diverse roles throughout the CNS exemplifies the presence of common underlying pathways responsible for neuronal development. Although many different genetic mutations and disrupted pathways lead to syndromes associated with ASD, there is significant overlap in their molecular and electrophysiological deficits. Specific deficits in synaptic function and plasticity in glutamate signaling have been consistently documented in various forms of ASD using mouse and human neuronal models and have been rescued with IGF-1. The link between synapse dysfunction and ASD suggest that treatment with IGF-1 may also have implications for ASD associated with disruptions in common underlying pathways. Preliminary studies in children with PMS and Rett syndrome have been successful, and IGF-1 may also be a promising therapeutic candidate in other single gene causes of ASD and perhaps in idiopathic ASD; a trial is underway with IGF-1 in ASD defined broadly (ClinicalTrials.gov Identifier: NCT01970345). Although definitive studies are needed, pilot data suggest the promise of IGF-1 in neurodevelopmental disorders associated with ASD.

    Highlights

    • IGF-1 is necessary for proper development of the central nervous system
    • IGF-1 dysregulation leads to neuronal dysfunction and severe developmental disorders
    • IGF-1 may be a safe and potentially effective treatment for several CNS disorders



    Thanks pgb thanked for this post
    Likes pgb liked this post
     
    Author: Ben Presser
    Ph.D. P.E.D. Kinesiology
    Intramuscular Injection Certified

    Aromatase Inhibitors, Post Cycle Therapy, Stenabolic, GW, Osta, LGD, S4 and IGF 1 Store

  2. #2
    Ph.D. P.E.D. Kinesiology Intramuscular Injection Certified Board Certified MD Presser's Avatar
    Join Date
    May 2002
    Posts
    37,668
    M-Chem Coin = $1
    124
    Rep Power
    10

    Default

    Igf treatment for CNS DISORDERS
    Author: Ben Presser
    Ph.D. P.E.D. Kinesiology
    Intramuscular Injection Certified

    Aromatase Inhibitors, Post Cycle Therapy, Stenabolic, GW, Osta, LGD, S4 and IGF 1 Store

+ Post New Thread

Similar Threads

  1. Dealing with Eating Disorders
    By drtbear1967 in forum Female Fitness Forum
    Replies: 3
    Last Post: 06-28-2018, 04:29 AM
  2. Sex Chromosomes, Chromosome Disorders And Brain/Psychiatric Disorders (Area-1255 EXCLUSIVE!)
    By Area 1255 in forum Bodybuilding Steroid & Training Articles
    Replies: 1
    Last Post: 04-24-2018, 03:39 PM
  3. Replies: 0
    Last Post: 04-19-2018, 08:29 AM
  4. Experimental Drug Achieves Unprecedented Weight Loss, Clinical Trial Finds
    By big in vegas in forum Anabolic Steroid Discussion
    Replies: 2
    Last Post: 04-13-2011, 07:13 PM
  5. Who would step up for a human clinical trial??
    By The Dude in forum Anabolic Steroid Discussion
    Replies: 10
    Last Post: 08-11-2009, 07:37 PM

Tags for this Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •